ASX - By Stock
|
MSB |
Re:
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
|
|
Valueformoney
|
317 |
138K |
60 |
23/07/24 |
23/07/24 |
ASX - By Stock
|
317
|
138K
|
60
|
|
ASX - By Stock
|
MSB |
Re:
CLBP Trial 2024
|
|
Valueformoney
|
13 |
5.8K |
18 |
19/07/24 |
19/07/24 |
ASX - By Stock
|
13
|
5.8K
|
18
|
|
ASX - By Stock
|
MSB |
Re:
CLBP Trial 2024
|
|
Valueformoney
|
13 |
5.8K |
6 |
19/07/24 |
19/07/24 |
ASX - By Stock
|
13
|
5.8K
|
6
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Regulatory Approval to Commence Sales for Striate in Canada
|
|
Valueformoney
|
23 |
7.3K |
10 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
23
|
7.3K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Valueformoney
|
5.7K |
2.8M |
5 |
05/07/24 |
05/07/24 |
ASX - By Stock
|
5.7K
|
2.8M
|
5
|
|
ASX - By Stock
|
PNV |
Re:
30th June 2024 Share Price Prediction
|
|
Valueformoney
|
232 |
86K |
3 |
29/06/24 |
29/06/24 |
ASX - By Stock
|
232
|
86K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Valueformoney
|
943 |
405K |
11 |
27/06/24 |
27/06/24 |
ASX - By Stock
|
943
|
405K
|
11
|
|
ASX - By Stock
|
PNV |
Re:
30th June 2024 Share Price Prediction
|
|
Valueformoney
|
232 |
86K |
2 |
26/06/24 |
26/06/24 |
ASX - By Stock
|
232
|
86K
|
2
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Investor Presentation
|
|
Valueformoney
|
611 |
114K |
3 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
611
|
114K
|
3
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Third Revenue Generating Product to be Launched in SmrtGraft
|
|
Valueformoney
|
15 |
6.4K |
11 |
17/06/24 |
17/06/24 |
ASX - By Stock
|
15
|
6.4K
|
11
|
|
ASX - By Stock
|
OCC |
Re:
OCC Trading
|
|
Valueformoney
|
1.7K |
536K |
16 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
1.7K
|
536K
|
16
|
|
ASX - By Stock
|
OCC |
Re:
OCC Trading
|
|
Valueformoney
|
1.7K |
536K |
3 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
1.7K
|
536K
|
3
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Successful OrthoATI clinical trial
|
|
Valueformoney
|
55 |
16K |
1 |
25/05/24 |
25/05/24 |
ASX - By Stock
|
55
|
16K
|
1
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Successful OrthoATI clinical trial
|
|
Valueformoney
|
55 |
16K |
2 |
25/05/24 |
25/05/24 |
ASX - By Stock
|
55
|
16K
|
2
|
|
ASX - By Stock
|
CYP |
Re:
Stem Cell News
|
|
Valueformoney
|
517 |
125K |
2 |
28/04/24 |
28/04/24 |
ASX - By Stock
|
517
|
125K
|
2
|
|
ASX - By Stock
|
CYP |
Re:
Stem Cell News
|
|
Valueformoney
|
517 |
125K |
4 |
26/04/24 |
26/04/24 |
ASX - By Stock
|
517
|
125K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Appendix 3Y for Jane Bell
|
|
Valueformoney
|
38 |
19K |
0 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
38
|
19K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Appendix 3Y for Jane Bell
|
|
Valueformoney
|
38 |
19K |
34 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
38
|
19K
|
34
|
|
ASX - By Stock
|
CYP |
Re:
Ann: DFU Clinical Trial Enrolment Complete
|
|
Valueformoney
|
33 |
9.3K |
8 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
33
|
9.3K
|
8
|
|
ASX - By Stock
|
OCC |
Re:
Stem Cell Therapy advancements
|
|
Valueformoney
|
475 |
165K |
13 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
475
|
165K
|
13
|
|
ASX - By Stock
|
CYP |
Re:
Ann: EU Approval for Phase 2 CYP-001 Trial in GvHD
|
|
Valueformoney
|
8 |
1.9K |
7 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
8
|
1.9K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Valueformoney
|
18K |
6.9M |
2 |
04/01/24 |
04/01/24 |
ASX - By Stock
|
18K
|
6.9M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Valueformoney
|
18K |
6.9M |
2 |
03/01/24 |
03/01/24 |
ASX - By Stock
|
18K
|
6.9M
|
2
|
|
ASX - By Stock
|
PNV |
Re:
30th June 2024 Share Price Prediction
|
|
Valueformoney
|
232 |
86K |
6 |
03/07/23 |
03/07/23 |
ASX - By Stock
|
232
|
86K
|
6
|
|
ASX - By Stock
|
PNV |
Re:
PNV - Chart
|
|
Valueformoney
|
19K |
11M |
1 |
25/06/23 |
25/06/23 |
ASX - By Stock
|
19K
|
11M
|
1
|
|
ASX - By Stock
|
PNV |
Re:
PNV - Chart
|
|
Valueformoney
|
19K |
11M |
0 |
25/06/23 |
25/06/23 |
ASX - By Stock
|
19K
|
11M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Schedules GvHD Pre-License Manufacturing Inspection
|
|
Valueformoney
|
275 |
113K |
12 |
19/05/23 |
19/05/23 |
ASX - By Stock
|
275
|
113K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Valueformoney
|
18K |
6.9M |
9 |
11/05/23 |
11/05/23 |
ASX - By Stock
|
18K
|
6.9M
|
9
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Valueformoney
|
10K |
3.2M |
73 |
10/05/23 |
10/05/23 |
ASX - By Stock
|
10K
|
3.2M
|
73
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Valueformoney
|
10K |
3.2M |
10 |
06/05/23 |
06/05/23 |
ASX - By Stock
|
10K
|
3.2M
|
10
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Valueformoney
|
18K |
6.9M |
15 |
06/04/23 |
06/04/23 |
ASX - By Stock
|
18K
|
6.9M
|
15
|
|
ASX - By Stock
|
OCC |
Re:
OCC Trading
|
|
Valueformoney
|
1.7K |
536K |
5 |
27/03/23 |
27/03/23 |
ASX - By Stock
|
1.7K
|
536K
|
5
|
|
ASX - By Stock
|
OCC |
Re:
OCC Trading
|
|
Valueformoney
|
1.7K |
536K |
0 |
27/03/23 |
27/03/23 |
ASX - By Stock
|
1.7K
|
536K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Valueformoney
|
18K |
6.9M |
7 |
04/03/23 |
04/03/23 |
ASX - By Stock
|
18K
|
6.9M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Second Quarter Financial Results Webcast
|
|
Valueformoney
|
56 |
19K |
9 |
27/02/23 |
27/02/23 |
ASX - By Stock
|
56
|
19K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Second Quarter Financial Results Webcast
|
|
Valueformoney
|
56 |
19K |
16 |
27/02/23 |
27/02/23 |
ASX - By Stock
|
56
|
19K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Valueformoney
|
18K |
6.9M |
2 |
26/01/23 |
26/01/23 |
ASX - By Stock
|
18K
|
6.9M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Valueformoney
|
18K |
6.9M |
2 |
26/01/23 |
26/01/23 |
ASX - By Stock
|
18K
|
6.9M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Valueformoney
|
18K |
6.9M |
0 |
26/01/23 |
26/01/23 |
ASX - By Stock
|
18K
|
6.9M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Valueformoney
|
18K |
6.9M |
0 |
26/01/23 |
26/01/23 |
ASX - By Stock
|
18K
|
6.9M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Valueformoney
|
18K |
6.9M |
2 |
26/01/23 |
26/01/23 |
ASX - By Stock
|
18K
|
6.9M
|
2
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Investor Presentation
|
|
Valueformoney
|
45 |
17K |
3 |
21/11/22 |
21/11/22 |
ASX - By Stock
|
45
|
17K
|
3
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Investor Presentation
|
|
Valueformoney
|
45 |
17K |
13 |
21/11/22 |
21/11/22 |
ASX - By Stock
|
45
|
17K
|
13
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Remplir Gains Australian Reimbursement
|
|
Valueformoney
|
62 |
19K |
7 |
03/11/22 |
03/11/22 |
ASX - By Stock
|
62
|
19K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Interesting MSC's Article
|
|
Valueformoney
|
20 |
4.4K |
11 |
19/07/22 |
19/07/22 |
ASX - By Stock
|
20
|
4.4K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Growing doubt on COVID-19 Application
|
|
Valueformoney
|
4.7K |
1.1M |
8 |
16/07/22 |
16/07/22 |
ASX - By Stock
|
4.7K
|
1.1M
|
8
|
|
ASX - By Stock
|
MSB |
Re:
MSB All-time low Party Thread
|
|
Valueformoney
|
396 |
110K |
12 |
04/07/22 |
04/07/22 |
ASX - By Stock
|
396
|
110K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
CHF - MSB's Dark Horse with Multi-billion dollar potential
|
|
Valueformoney
|
516 |
157K |
5 |
30/01/22 |
30/01/22 |
ASX - By Stock
|
516
|
157K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
CHF - MSB's Dark Horse with Multi-billion dollar potential
|
|
Valueformoney
|
516 |
157K |
1 |
30/01/22 |
30/01/22 |
ASX - By Stock
|
516
|
157K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
CHF - MSB's Dark Horse with Multi-billion dollar potential
|
|
Valueformoney
|
516 |
157K |
4 |
30/01/22 |
30/01/22 |
ASX - By Stock
|
516
|
157K
|
4
|
|